Diaceutics PLC is pleased to report its audited results for the year ended 31 December 2019. The Company has had a transformative year with the successful IPO and further client, regional, project and brand growth leading to a growth in revenue and profitability, excluding exceptional costs.
In 2019 we invested further in three key pillars which will ensure the company can continue its mission to become the leading provider of diagnostic commercialisation services to the pharma industry as it continues to focus on precision medicine; these include deepening our testing datalake, advancing our Nexus platform in anticipation of a launch in Q4 2020 and targeted regional data and services expansion to the top 15 pharma markets. Diaceutics’ focus over the past 24 months and in particular the last 12 months has been to ensure that it possesses the necessary infrastructure required to service its global pharma companies on an increasing scale as they transform their R&D pipelines towards precision medicine, a market anticipated to double from $39bn in 2018 to $80bn in 2026.(1)
Report Preview
